Copyright Reuters
Under the deal, the companies would offer the lowest dose of their respective obesity drugs at $149 per month, the report said, citing sources familiar with the matter. The agreement can be announced this week, it added. Sign up here. In return, the drugs would gain coverage under Medicare, a federal health insurance program in the U.S. for people aged 65 and older, which would open up a huge new set of reimbursement, according to the report. Lilly and Novo did not immediately respond to Reuters requests for comment. Reporting by Sriparna Roy in Bengaluru; Editing by Leroy Leo
